BioMarin Pharmaceutical Announces Resignation of Chief Accounting Officer: Erin Burkhart to Depart on September 2, 2025.

BioMarin Pharmaceutical has announced the resignation of Chief Accounting Officer Erin Burkhart, effective September 2. The company will search for her successor, with Executive Vice President and Chief Financial Officer Brian Mueller assuming her responsibilities. Analysts have a buy rating and a $97.00 price target for the stock. BioMarin's overall stock score reflects strong financial performance and positive strategic developments, with a reasonable valuation supporting a solid investment case.

Biomarin Pharmaceutical (BMRN) has reported robust second-quarter (Q2) 2025 earnings, with net income surging 124% to $240.53 million and earnings per share (EPS) rising 123% to $1.25. These figures significantly exceeded market expectations. The company's revenue grew 15.9% to $825.41 million, driven by strong demand for its therapies, particularly VOXZOGO, VIMIZIM, and Enzyme Therapies, which saw 20%+ year-over-year growth. KUVAN revenue declined due to ongoing generic competition [1].

The company also raised its full-year 2025 guidance, projecting total revenues between $3.125 billion and $3.200 billion, with non-GAAP operating margins expected to be between 33% and 34%. Non-GAAP diluted EPS is anticipated to range between $4.40 and $4.55. These updates reflect sustained growth and operational efficiency, as well as the anticipated benefits of international adoption of VOXZOGO and demand for enzyme therapies [1].

The stock price of Biomarin declined by 2.22% post-earnings but showed a positive trend over the past week with a 6.35% gain and a 7.70% increase month-to-date. This suggests a mixed short-term reaction, but overall investor sentiment remains bullish [1].

Wall Street Zen upgraded Biomarin to a "strong-buy" rating, indicating increased confidence among analysts in the company's prospects. The company has a market capitalization of $11.01 billion and shows strong institutional ownership, with 98.71% of the stock held by institutional investors. Analysts have a buy rating and a $97.00 price target for the stock, reflecting strong financial performance and positive strategic developments [2].

Additionally, Biomarin completed the acquisition of Inozyme in July 2025, adding BMN 401, a potential first-in-disease treatment for ENPP1 Deficiency. The company also announced plans to expand PALYNZIQ age eligibility for treating adolescents with phenylketonuria in the second half of 2025, underscoring its commitment to innovation and market expansion [1].

References:
[1] https://www.ainvest.com/news/biomarin-2025-q2-earnings-net-income-surges-124-2508/
[2] https://www.marketbeat.com/instant-alerts/biomarin-pharmaceutical-nasdaqbmrn-upgraded-by-wall-street-zen-to-strong-buy-rating-2025-08-09/